MedTrace Logo

Colchicine for Diabetic Nephropathy Trial

NCT02442921 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-05-09

No results posted yet for this study

Summary

Forty patients with diabetic nephropathy will be treated with colchicine up to 2 mg, or placebo, for 18 months. A follow up will be performed after 12 additional months. The primary outcome will be a significant reduction or stabilization of proteinuria during the 18 month treatment period.

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

Colchicine

up to 2mg of Colchicine daily

DRUG

Placebo

Daily placebo

Sponsors & Collaborators

  • D-Cure, Israel

    collaborator INDUSTRY

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Shaye Kivity, MD · Sheba Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-22
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442921 on ClinicalTrials.gov